Results 81 to 90 of about 8,252,790 (324)
Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs
Antibody-drug conjugates (ADCs), often referred to as “intelligent biological missiles,” have garnered significant attention in the rapidly evolving landscape of cancer therapy. ADCs represent a sophisticated approach by integrating monoclonal antibodies
Dan Wu +9 more
doaj +1 more source
ABSTRACT Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia.
Jinwoo Kim +11 more
wiley +1 more source
Adaptive Minimax-Regret Treatment Choice, With Application To Drug Approval [PDF]
Suppose that there are two treatments for a condition. One is the status quo, whose properties are known from experience and the other is an innovation, whose properties are not known initially.
Charles F. Manski
core
A review of the regulatory framework for personalized bacteriophages registration
The increasing trend in antimicrobial resistance of pathogenic bacteria dictates the need for alternative solutions. Bacteriophages are bacterial viruses that kill their hosts during the lifecycle.
N. N. Landyshev +5 more
doaj +1 more source
Supporting U.S. Food and Drug Administration Approval of Cancer Drugs Background: In the United States, African American persons have the highest death rate and lowest survival rate of any racial or ethnic group for most types of cancer.
Samer al Hadidi +3 more
semanticscholar +1 more source
ABSTRACT Introduction Peritoneal dialysis (PD) is an established home‐based kidney replacement therapy (KRT), but its uptake remains low in Japan. We evaluated whether individualized education in a dedicated outpatient clinic was associated with the initiation of PD.
Yasuko Ito +7 more
wiley +1 more source
Is It Possible to Have Cheaper Drugs and Preserve the Incentive to Innovate: Reforming the Drug Approval Process According to Market Principles [PDF]
This paper argues that drugs are expensive not because of a lack of competition among research-based pharmaceutical companies, but because of a lack of competition in the drug approval process.
Robert Sauer, Corinne Sauer
core
In 2025, it will be 30 years since the initial clinical approval of pegylated liposomal doxorubicin (PLD) by the Food and Drug Administration. PLD predated the field of nanomedicine and became a model nanomedicine setting key pharmacological principles ...
A. Gabizon +3 more
semanticscholar +1 more source
ABSTRACT Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid‐lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non‐drug treatment using double‐filtration plasmapheresis (DFPP) on CD14+
Yun Cheng +3 more
wiley +1 more source
ABSTRACT Instruction Tenapanor potentially affects fluid volume and blood pressure. This study explored its effects on these parameters in patients undergoing peritoneal dialysis (PD). Methods We conducted a single‐arm, prospective observational study that enrolled 10 patients on PD with hyperphosphatemia who were newly initiated on tenapanor.
Shun Yoshida +11 more
wiley +1 more source

